The results showed that there were three different subtypes of high-grade myometrial invasive bladder tumors: subtype A was “centralized amplification,” subtype B was “mastoid CDKN2A deletion FGFR3 mutation,” and subtype C was “TP53/cell cycle mutant.” Wu et al. went on to identify 99 DEIGs based on TP53 mutation status, design and validate TIPS such as ORM1, PTHLH, and CTSE, and effectively construct prediction models in TCGA and GEO databases to identify poor high-risk prognosis groups [37]. The gene discussed is FGFR3; the disease is urinary bladder neoplasm.